Percent of prostate needle biopsy cores with cancer is a significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: Results from the SEARCH database

Journal of Urology

Volumn 169, Issue 6, 2003, Pages 2136-2141

  Freedland, Stephen J ^a   Aronson, William J ^b   Terris, Martha K ^b   Kane, Christopher J ^b   Amling, Christopher L ^b   Dorey, Frederick ^b   Presti Jr , Joseph C ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Biopsy, needle; Prostate specific antigen, recurrence; Prostatectomy; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEEDLE BIOPSY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES;

EID: 0038626279     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000065588.82511.06     Document Type: Article

References (20)

1. Kattan, M. W., Eastham, J. A., Stapleton, A. M., Wheeler, T. M. and Scardino, P. T.: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst, 90: 766, 1998
2. Partin, A. W., Kattan, M. W., Subong, E. N., Walsh, P. C., Wojno, K. J., Oesterling, J. E. et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA, 277: 1445, 1997
3. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Blank, K., Broderick, G. A. et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA, 280: 969, 1998
4. Aihara, M., Lebovitz, R. M., Wheeler, T. M., Kinner, B. M., Ohori, M. and Scardino, P. T.: Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate cancer. J Urol, 151: 1558, 1994
5. Furuya, Y., Fuse, H., Nagakawa, O. and Masai, M.: Preoperative parameters to predict tumor volume in Japanese patients with nonpalpable prostate cancer. Int J Clin Oncol, 7: 109, 2002
6. Borirakchanyavat, S., Bhargava, V., Shinohara, K., Toke, A., Carroll, P. R. and Presti, J. C., Jr.: Systematic sextant biopsies in the prediction of extracapsular extension at radical prostatectomy. Urology, 50: 373, 1997
7. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Fondurulia, J., Chen, M. H. et al: Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol, 18: 1164, 2000
8. Presti, J. C., Jr., Shinohara, K., Bacchetti, P., Tigrani, V. and Bhargava, V.: Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology, 52: 1079, 1998
9. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Silver, B., Henry, L. et al: Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer. Mol Urol, 4: 171, 2000
10. Grossfeld, G. D., Latini, D. M., Lubeck, D. P., Broering, J. M., Li, Y. P., Mehta, S. S. et al: Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaP-SURE. Urology, 59: 560, 2002
11. Freedland, S. J., Amling, C. L., Dorey, F., Kane, C. J., Presti, J. C., Jr., Terris, M. K. et al: Race as an outcome predictor following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Urology, 60: 670, 2002
12. Beahrs, O. H., Henson, D. E. and Hutter, R. V. P.: American Joint Committee on Cancer Manual for Staging Cancer. Philadelphia: J. B. Lippincott, 1992
13. Terris, M. K.: Sensitivity and specificity of sextant biopsies in the detection of prostate cancer: preliminary report. Urology, 54: 486, 1999
14. Freedland, S. J., Jalkut, M., Dorey, F., Sutter, M. E. and Aronson, W. J.: Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center. Urology, 56: 87, 2000
15. Borboroglu, P. G., Comer, S. W., Riffenburgh, R. H. and Amling, C. L.: Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol, 163: 158, 2000
16. Nelson, C. P., Rubin, M. A., Strawderman, M., Montie, J. E. and Sanda, M. G.: Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology, 59: 740, 2002
17. Freedland, S. J., Csathy, G. S., Dorey, F. and Aronson, W. J.: Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol, 167: 516, 2002
18. Ravery, V., Chastang, C., Toublanc, M., Boccon-Gibod, L., Delmas, V. and Boccon-Gibod, L.: Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer. Eur Urol, 37: 449, 2000
19. Linson, P. W., Lee, A. K., Doytchinova, T., Chen, M. H., Weinstein, M. H., Richie, J. P. et al: Percentage of core lengths involved with prostate cancer: does it add to the percentage of positive prostate biopsies in predicting postoperative prostatespecific antigen outcome for men with intermediate-risk prostate cancer? Urology, 59: 704, 2002
20. Graefen, M., Haese, A., Pichlmeier, U., Hammerer, P. G., Noldus, J., Butz, K. et al: A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol, 165: 857, 2001